Propanc Financial Statements From 2010 to 2024
| PPCB Stock | USD 0.0002 0.0001 33.33% |
Check Propanc Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Propanc Biopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Propanc financial statements analysis is a perfect complement when working with Propanc Biopharma Valuation or Volatility modules.
Propanc |
Propanc Biopharma Company Return On Asset Analysis
Propanc Biopharma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Propanc Biopharma Return On Asset | -13.07 |
Most of Propanc Biopharma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Propanc Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Propanc Biopharma has a Return On Asset of -13.0742. This is 49.42% higher than that of the Biotechnology sector and 44.6% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Propanc Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Propanc Biopharma's current stock value. Our valuation model uses many indicators to compare Propanc Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Propanc Biopharma competition to find correlations between indicators driving Propanc Biopharma's intrinsic value. More Info.Propanc Biopharma is considered to be number one stock in return on asset category among its peers. It also is rated top company in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Propanc Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Propanc Biopharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Propanc Biopharma Financial Statements
Propanc Biopharma stakeholders use historical fundamental indicators, such as Propanc Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Propanc Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Propanc Biopharma's assets and liabilities are reflected in the revenues and expenses on Propanc Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Propanc Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia. Propanc Biopharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Propanc Pink Sheet
Propanc Biopharma financial ratios help investors to determine whether Propanc Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Propanc with respect to the benefits of owning Propanc Biopharma security.